Processa Pharmaceuticals, Inc. Overview
Pro stress-test →Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer therapy drugs that are modifications of existing FDA-approved oncology drugs, altering their metabolism and distribution while maintaining existing anti-cancer mechanisms. The company is advancing NGC-Cap (PCS6422 + capecitabine) for advanced or metastatic breast cancer.
Strategic Profile
Pro stress-test →The company completed enrollment of 20 patients in its randomized Phase 2 study of NGC-Cap in advanced or metastatic breast cancer, with formal interim analysis expected in Q1 2026. Preliminary Phase 2 data show increased exposure to capecitabine metabolites with a safety profile comparable to capecitabine monotherapy.
Competitive Landscape
Pro stress-test →Processa competes in the oncology-focused drug development space against larger biopharmaceutical companies developing next-generation cancer therapeutics and combination therapies. Direct competitors include companies developing capecitabine combinations and novel approaches to breast cancer treatment, though Processa's niche focus on metabolite-enhancing modifications of FDA-approved drugs differentiates its approach from broader oncology development programs.
Industry Context
Processa Pharmaceuticals, Inc. operates in Oncology drug development.
Key facts
Founded: 2009 · Headquarters: Hanover, US · Employees: 12 · Revenue: $0 · Market cap: $7.29M